AZD3229 (C007B-021150)

InformationAZD3229 is a potent, pan-Kit (c-Kit) mutantinhibitor with potent single digit nM growth inhibition against a diverse panel of mutant Kit (c-Kit) driven Ba/F3 cell lines (GI50=1-50 nM), with good margin to KDR-driven effects. It also inhibitsPDGFR mutants(Tel-PDGFRα, Tel-PDGFRβ, V561D/D842V).TargetsKit ; PDGFRα ; PDGFRβIn vivoIn preclinical species, bioavailability is high and clearance low across all of mouse, rat, and dog. Volume of distribution is low consistent with the neutral structure. In in vivo models using Ba/F3 cell lines, AZD3229 at a dose of 20 mg/kg b.i.d induces tumor volume regression more effectively than regorafenib at a dose of 100 mg/kg q.d and imatinib.

Specifications and Purity: ≥98%

Molecular Formula: C24H26FN7O3

Molecular Weight: 479.51

PubChem CID: 134814269

Isomeric SMILES: CC(C)C1=CN(N=N1)CC(=O)NC2=CC=C(C=C2)NC3=NC=NC4=C3C(=CC(=C4)OCCOC)F